Related Experiment Video
Updated: Jan 12, 2026
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
Published on: January 12, 2016
Cafeic acid benzylidene hydrazides as novel procaspase-3 activators: Rational design, synthesis, and mechanistic
Zhongyuan Guo1, Run Wang2, Qingsi Zhao3
1Institue of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; College of Medicine, Henan University of Chinese Medicine, Henan, Zhengzhou 450046, China.
Abstract:
Caspase-3 is an essential intracellular protein mediating cell apoptosis and a key target in the apoptosis pathway of cancer cell. Activating its existing inactive proenzyme, Procaspase-3, induces apoptosis in various tumor cells and has emerged as a promising cancer therapy strategy. In this study, a novel series of hybrid caffeic acid benzylidene hydrazide derivatives were rationally designed and evaluated as potent procaspase-3 activators. Caffeic acid was first identified as a privileged scaffold for procaspase-3 activation through structure-based pharmacophore modeling. By hybridizing this natural product scaffold with optimized structural elements from PAC-1, a reference procaspase-3 activator, 28 target compounds (K-01 ∼ K-28) were successfully synthesized. Molecular modeling studies revealed that these hybrid compounds possess enhanced zinc chelation capacity, a crucial mechanism for procaspase-3 activation. The antiproliferative activity of these compounds was systematically evaluated against A549 (non-small cell lung cancer) and A375 (melanoma) cell lines. Among the synthesized derivatives, 23 compounds (82.1 %) demonstrated superior potency compared to PAC-1 (positive control). Notably, compounds K-15 and K-22 exhibited significant activity against A549 cells (IC50 = 3.96 ± 1.07 μM and 5.60 ± 2.20 μM, respectively) while maintaining minimal cytotoxicity toward human lung epithelial cells (BEAS-2B), as evidenced by high cell viability rates of 91.99 % and 95.37 %. Direct procaspase-3 activation by these lead compounds was further confirmed through mechanistic studies. In silico ADMET profiling demonstrated that the lead compound K-15 exhibits optimal pharmacokinetic properties, including moderate aqueous solubility (Level 2), negligible blood-brain barrier penetration (Level 4), absence of hepatotoxicity risk, and favorable intestinal absorption (Level 1). All compounds were confirmed to be non-inhibitors of CYP2D6, indicating minimal potential for drug-drug interactions. These results demonstrate that the hybrid molecular design strategy effectively combines the pharmacophoric advantages of both natural products and synthetic activators. The developed procaspase-3 activators exhibit improved therapeutic potential and represent promising candidates for further development as targeted anticancer agents modulating the caspase-3 activation pathway.
Insights
Novel hybrid compounds activating procaspase-3 (an apoptosis protein) show potent anticancer effects against lung and melanoma cells. These promising drug candidates offer a new strategy for cancer therapy with favorable safety profiles.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Caspase-3 activation is a critical target for cancer therapy, inducing apoptosis in tumor cells.
- Procaspase-3, the inactive precursor, can be activated to trigger cancer cell death.
- Developing potent and safe procaspase-3 activators is a key strategy in oncology.
Purpose of the Study:
- To design and synthesize novel hybrid caffeic acid benzylidene hydrazide derivatives as procaspase-3 activators.
- To evaluate the antiproliferative activity and mechanism of action of these novel compounds.
- To assess the pharmacokinetic properties and safety profile of lead compounds.
Main Methods:
- Structure-based pharmacophore modeling identified caffeic acid as a privileged scaffold.
- Hybridization of caffeic acid with PAC-1 structural elements yielded 28 target compounds.
- Antiproliferative assays (A549, A375 cells), mechanistic studies, and in silico ADMET profiling were performed.
Main Results:
- 23 out of 28 synthesized compounds (82.1%) showed superior potency to the control PAC-1.
- Compounds K-15 and K-22 demonstrated significant activity against A549 lung cancer cells (IC50 values ~4-6 μM) with minimal cytotoxicity to normal lung cells.
- Lead compound K-15 exhibited favorable in silico pharmacokinetic properties and no CYP2D6 inhibition, suggesting low drug-drug interaction potential.
Conclusions:
- The hybrid molecular design strategy successfully combined pharmacophoric features for enhanced procaspase-3 activation.
- The novel derivatives, particularly K-15 and K-22, are potent anticancer agents targeting the caspase-3 pathway.
- These compounds represent promising candidates for further development as targeted cancer therapeutics.
